(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 December 2011 (08.12.2011)

PCT

(10) International Publication Number
WO 2011/151431 A1

(51) **International Patent Classification**:
A61K 39/145 (2006.01) ***A61K 9/00*** (2006.01)
A61P 37/04 (2006.01)

(21) **International Application Number**:
PCT/EP2011/059167

(22) **International Filing Date**:
2 June 2011 (02.06.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
1009273.2 3 June 2010 (03.06.2010) GB

(71) **Applicant** *(for all designated States except US)*: **GLAXOSMITHKLINE BIOLOGICALS S.A.** [BE/BE]; rue de l'Institut 89, B-1330 Rixensart (BE).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **OUAKED, Nadia** [CA/CA]; GlaxoSmithKline Biologicals North America, 525 Blvd Cartier West, Laval, Québec H7V 3S8 (CA). **PLANTE, Martin** [CA/CA]; GlaxoSmithKline Biologicals North America, 525 Blvd Cartier West, Laval, Québec H7V 3S8 (CA). **LAROCQUE, Daniel** [CA/CA]; GlaxoSmithKline Biologicals North America, 525 Blvd Cartier West, Laval, Québec H7V 3S8 (CA). **MALLETT, Corey Patrick** [CA/CA]; GlaxoSmithKline Biologicals North America, 525 Blvd Cartier West, Laval, Québec H7V 3S8 (CA).

(74) **Agent**: **ROBERTSON, James Stuart**; GlaxoSmithKline, Global Patents CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2011/151431 A1

(54) **Title**: ORAL VACCINE COMPRISING AN ANTIGEN AND A TOLL-LIKE RECEPTOR AGONIST

(57) **Abstract**: The present invention provides an immunogenic composition comprising one or more antigens and a Toll-like receptor (TLR) agonist in an orally (e.g. sublingually) administered composition.